Why We’re Backing Warp
Summary
- Warp launched today with a Series A round led by Lightspeed to build AI-driven robotic labs for drug discovery chemistry.
- The company aims to accelerate drug discovery & bring this work back to the US amid rising costs & low approval rates.
- Drug development is slow because manual lab work rarely exceeds ten reactions per day & lacks compounding process expertise.
- Western pharma currently outsources most chemistry offshore to China, but the 2025 BIOSECURE Act & recent Department of War designations are pushing for domestic alternatives.
- US companies face an estimated eight-year gap to replace offshore partners without disrupting programs.
- AI models are limited by a lack of public data on failed experiments, which are critical for training accurate prediction models.
- Warp records all experimental steps including failures to optimize lab processes & train models to select the best compounds.
- Early operations involve expert chemists using AI tools, with robots gradually taking over repetitive tasks to scale operations 24/7.
- The founding team includes CEO Kevin Weil (ex-OpenAI), COO DJ Patil (ex-US Chief Data Scientist), CSO Sol Reisberg (20 years in medicinal chemistry), & co-founder Mano Paluri (ex-Meta AI).
- Advances in lab robotics & AI models now enable continuous learning loops that were previously impossible.
- Lightspeed invested due to Warp's unique position to capture the opportunity at the intersection of AI, robotics, & life sciences.
Warp builds AI-driven robotic labs that run drug discovery chemistry for pharma and biotech companies. Its goal is to both speed up drug discovery and bring this work back to the US.
- Keywords
- AI